enVVeno Medical Corporation
enVVeno Medical Corporation
Your view on NVNO
Overview
What the company does, where it operates, and who runs it.
About enVVeno Medical Corporation
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Robert A. Berman
- Headquarters
- 70 Doppler, Irvine, CA, US
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Robert A. Berman
- Headquarters
- 70 Doppler, Irvine, CA, US
enVVeno Medical Corporation, a medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of severe deep venous chronic venous insufficiency.
Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for enVVeno Medical Corporation, and the rating behind it. NVNO last traded at $10.49; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for enVVeno Medical Corporation. Starting points for enVVeno Medical Corporation: EPS -$23.43, beta 1.07 — an Medical - Devices name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for enVVeno Medical Corporation. enVVeno Medical Corporation does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for enVVeno Medical Corporation. Trailing twelve-month EPS for enVVeno Medical Corporation stands at -$23.43. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for enVVeno Medical Corporation. enVVeno Medical Corporation has reported as a listed company since 2018. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
enVVeno Medical Corporation valued side by side against its closest peers. enVVeno Medical Corporation is measured against Medical - Devices peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold enVVeno Medical Corporation, and how their positions are changing. At a $173,116 market value, institutional positions materially move enVVeno Medical Corporation's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by enVVeno Medical Corporation executives and directors. Shares of enVVeno Medical Corporation have traded between $0.31 and $5.62 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming enVVeno Medical Corporation. enVVeno Medical Corporation is a $173,116 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming enVVeno Medical Corporation. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for enVVeno Medical Corporation. Coverage tracks enVVeno Medical Corporation within Medical - Devices (Healthcare). Press releases and market coverage, newest first.